Yao Manman, Fang Baoxia, Yang Jinguo, Chen Peng, Chen Fuchao
Sinopharm Dongfeng General Hospital, Hubei University of Medicine, Shiyan, Hubei, China.
School of Pharmaceutical Sciences, Hubei University of Medicine, Shiyan, Hubei, China.
Front Pharmacol. 2024 Feb 7;15:1247646. doi: 10.3389/fphar.2024.1247646. eCollection 2024.
Patient-controlled intravenous analgesia (PCIA) can alleviate pain to some extent, and several randomized controlled trials (RCTs) have examined the efficacy of esketamine-assisted sufentanil in postoperative PCIA. In this research, we conducted a meta-analysis of relevant RCTs to compare the effect and safety of esketamine-sufentanil sufentanil alone for postoperative PCIA. We systematically searched the Cochrane Library, PubMed, Embase, Web of Science, CNKI, and other libraries up to December 2023 to screen out RCTs examining the use of esketamine combined with sufentanil for PCIA. We analysed analgesia scores, sedation scores, adverse drug reactions and depression scores as outcome indicators. This meta-analysis included 32 RCTs. The results of the meta-analysis were as follows. 1) Visual Analog Scale: The VAS scores at 6, 12, 24, and 48 h were lower in the esketamine-sufentanil group than in the sufentanil alone group, and significant differences were found at all time points ( < 0.05). 2) Ramsay Sedation Scale: The sedation score of the esketamine-sufentanil group at 48 h after surgery was higher than that of the sufentanil group alone [mean difference (MD) = -0.09 points, confidence interval (): (-0.26, -0.07), = 0.27], but this difference was not significant ( > 0.05). 3) Safety: Compared with sufentanil alone, the incidence rates of postoperative nausea-vomiting, dizziness-headache, skin pruritus and respiratory depression were significantly lower in the esketamine-sufentanil group. 4) depression: The reduction in depression scores were significantly greater in the esketamine-sufentanil group than in the sufentanil alone group at 3 days [MD = -1.35 points, : (-1.89, -0.81), < 0.00001] and 7 days [MD = -1.29 points, : (-2.42, -0.16), = 0.03]. The meta-analysis showed that the use of esketamine combined with sufentanil for postoperative PCIA could improve postoperative analgesia, alleviate depression and reduce the rate of postoperative adverse reactions, but there was no significant difference in sedation.
患者自控静脉镇痛(PCIA)在一定程度上可缓解疼痛,多项随机对照试验(RCT)已研究了艾司氯胺酮辅助舒芬太尼用于术后PCIA的疗效。在本研究中,我们对相关RCT进行了荟萃分析,以比较艾司氯胺酮 - 舒芬太尼与单用舒芬太尼用于术后PCIA的效果和安全性。我们系统检索了截至2023年12月的Cochrane图书馆、PubMed、Embase、Web of Science、中国知网等数据库,以筛选出研究艾司氯胺酮联合舒芬太尼用于PCIA的RCT。我们将镇痛评分、镇静评分、药物不良反应和抑郁评分作为结局指标进行分析。该荟萃分析纳入了32项RCT。荟萃分析结果如下。1)视觉模拟量表:艾司氯胺酮 - 舒芬太尼组术后6、12、24和48小时的VAS评分低于单用舒芬太尼组,各时间点均存在显著差异(P<0.05)。2)Ramsay镇静量表:艾司氯胺酮 - 舒芬太尼组术后48小时的镇静评分高于单用舒芬太尼组[平均差(MD)=-0.09分,置信区间(CI):(-0.26,-0.07),P = 0.27],但差异无统计学意义(P>0.05)。3)安全性:与单用舒芬太尼相比,艾司氯胺酮 - 舒芬太尼组术后恶心呕吐、头晕头痛、皮肤瘙痒和呼吸抑制的发生率显著降低。4)抑郁:术后3天[MD=-1.35分,CI:(-1.89,-0.81),P<0.00001]和7天[MD=-1.29分,CI:(-2.42,-0.16),P = 0.03]时,艾司氯胺酮 - 舒芬太尼组抑郁评分的降低幅度显著大于单用舒芬太尼组。荟萃分析表明,艾司氯胺酮联合舒芬太尼用于术后PCIA可改善术后镇痛、减轻抑郁并降低术后不良反应发生率,但在镇静方面无显著差异。